Navigation Links
Patients With Alzheimer’s Need To Be Checked For Visual Clarit

People suffering from Alzheimer’s disease can have loss of vision and hence their eyes must be //checked periodically to test their visual clarity.

Alzheimer’s disease affects the brain cells and slowly destroys them. The main symptoms of the disease are decreasing memory, ability to reason, creative abilities and learning powers. Patients suffering from Alzheimer’s disease are often disoriented too much to be able to take notice of the vision impairment.

The New Saint Louis University researchers who have conducted a survey of people suffering from Alzheimer’s said that amongst the patients of the disease who have been staying in the medical homes most have lost their glasses, broken them or have glasses that have not been updated to their new eye sight power. Some of them are too impaired to even ask for a replacement or report their decreasing ability to see things clearly.

The researchers are of the opinion that the loss of vision often may limit the mobility of the patients, cause them to feel disoriented and increase the chance of injury from falls. The researchers also recommend that the institutionalized care givers for the patients of Alzheimer’s disease should be actively involved in conducting regular tests for the patients’ eye sights, give them the right eye glasses, and take care of the spectacles for patients who are too impaired to do so.

Reference: Journal of the American Medical Directors Association, Jul 2005
'"/>




Page: 1

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patients often assume wrongly that they are allergic to penicillin
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. Hemochromatosis Patients Blood is Safe
9. Patients Pressure Would Result In Overprescription
10. Risk Of Decongestants In Hypertensive Patients
11. Interference helps Heart Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/25/2017)... ... September 25, 2017 , ... SyncDog, Inc., ... of SentinelSecure™, version 3.0, will be available in a managed cloud services model, ... SentinelSecure™ comes with several new enhancements including support for caller ID and network ...
(Date:9/25/2017)... ... 2017 , ... Nissar A. Darmani, PhD, has been awarded a record WesternU ... nausea and vomiting. Dr. Darmani is Associate Dean of Basic Medical Sciences in ... is from the National Cancer Institute (NCI) arm of the National Institutes of Health ...
(Date:9/25/2017)... ... September 25, 2017 , ... Just ask anyone old enough to remember what ... headgear so wired up and containing so much metal that jokes about radio reception ... its treatments can barely be observed. As a result, it’s now a billion-dollar industry ...
(Date:9/25/2017)... ... September 25, 2017 , ... Winners in ... announced on Friday, September 22 during a gala event in New York City. ... achievements and HR-related products and suppliers who help to create and drive great ...
(Date:9/25/2017)... ... September 25, 2017 , ... How many things are on your average daily ... “more than any sane human could possibly complete,” then you’re all too familiar with ... desperately trying to be everything to everybody all the time. , Self-proclaimed overly productive ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... BOTHELL, Wash. , Sept. 7, 2017   BioLife ... developer, manufacturer and marketer of proprietary clinical grade cell and ... media ("BioLife"), announces that Mike Rice , President and ... Rodman & Renshaw 19 th ... 3:25 p.m. Eastern time (12:25 p.m. Pacific time). The conference ...
(Date:9/6/2017)... -- Eli Lilly and Company (NYSE: LLY ... galcanezumab and lasmiditan, two investigational treatments for migraine, at ... taking place Sept. 7-10 in Vancouver ... data from an open-label study evaluating the safety and ... 240 mg) for the prevention of migraine. Galcanezumab is ...
(Date:9/5/2017)... , Sept. 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... has successfully concluded its meeting with the U.S. Food ... oral insulin formulation. ... the regulatory pathway for submission of ORMD-0801, would be ...
Breaking Medicine Technology: